Navigation Links
Transdel Pharmaceuticals to Present at Cowen and Company's 28th Annual Health Care Conference
Date:3/18/2008

LA JOLLA, Calif., March 18 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically administered medications, today announced that Dr. Juliet Singh, President and Chief Executive Officer, will present at Cowen and Company's 28th Annual Health Care Conference on Thursday, March 20, 2008 at 10:15 a.m. Eastern Time at The Marriott Copley Place in Boston, MA.

Dr. Singh will discuss the Company's business developments to date including the recent submission of the Phase 3 clinical study of Ketotransdel(TM) to the FDA.

Interested parties can access a live audio webcast and accompanying slide presentation via the Internet by visiting the Investor Relations section of the Company's Web site at http://www.transdelpharma.com. An archived presentation will be available on the Web site for 30 days.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) is a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically delivered medications. The Company's lead topical drug, Ketotransdel(TM), utilizes the Company's innovative patented proprietary Transdel(TM) cream formulation technology to facilitate the passage of ketoprofen, an NSAID, through the skin barrier to reach targeted underlying tissue where the drug exerts its prolonged localized anti-inflammatory and analgesic effect. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas.

Safe Harbor Statement

The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

Contact:

John Lomoro

Chief Financial Officer

Transdel Pharmaceuticals, Inc.

858-457-5300


'/>"/>
SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
2. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
3. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
4. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
5. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
6. SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results
7. Onyx Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
9. Drinking Water Association Discusses Pharmaceuticals in Water
10. Genesis Pharmaceuticals Changes Auditors
11. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Guide to FDA and EU Medical ... matter on which side of the Atlantic devicemakers do business, this fully updated and ... follow. , In addition to the full text of the FDA’s regulations in 21 ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... a one-day corporate governance program for mid-market executives as a kick-off to the ... held Sunday, Sept. 24, 2017 on the University of Pennsylvania campus, followed by ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, a Cincinnati ... to insurance assistance and financial planning services, is announcing the commencement of a ... the region facing financial crisis. , Matthew 25: Ministries (M25M) is an international ...
(Date:6/27/2017)... , ... June 27, 2017 , ... DrugDev ... is whether they can trust the sponsor to pay them correctly and on time. ... and CROs establish payment strategies that encourage sites to work on their studies. , ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... From June ... The three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... industry, how to connect with today’s savvy consumer, and the latest in hearing ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... , June 12, 2017 Kineta, Inc., a ... announced Kineta Vice President of R&D and Head ... the Pandemic Preparedness for the Northwest and Beyond ... held on June 14, 2017 from 8:30-10:30 AM PDT at ... Dr. Bedard will be joined by ...
(Date:6/8/2017)... 8, 2017  Less than a month ago, amateur ... 200,000 companies, including hospital networks, in over 150 countries. ... of the largest online extortion attempts ever recorded. With ... it is imperative that providers understand where the risks ... this — and many other very real cyber threats.  ...
(Date:6/7/2017)... June 6, 2017  Diplomat Specialty Infusion Group, a brand of ... to its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound ... a low level of pollutants. ... consumers and better serve our Iowa patients," ...
Breaking Medicine Technology: